Olvi-Vec Case Report Shows 16.7-Month PFS in Platinum-Relapsed SCLC
GNLX is trading near its 52-week low of $2.29 (10% above the low) on light trading volume (0.4× avg).
Summary
Genelux published a peer-reviewed case report in Frontiers in Oncology showing a platinum-relapsed small cell lung cancer patient achieved 16.7 months progression-free survival and an 84.6% tumor reduction after receiving systemically delivered Olvi-Vec followed by platinum rechallenge. This exceeds the patient's own first-line PFS of 14.3 months and historical outcomes for platinum rechallenge. The data support Olvi-Vec's potential to re-sensitize tumors to chemotherapy, a key mechanism for the company's lead asset. While a single-patient case report is not definitive efficacy evidence, the magnitude and durability are notable for a difficult-to-treat cancer. Enrollment continues in dose-escalation cohorts, with additional dose-finding updates expected in 2026. This follows the Q2 10-Q showing a widened loss and cash runway only into Q1 2027, making positive clinical data important for the company's outlook.
At the time of this announcement, GNLX was trading at $2.52 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $114M. The 52-week trading range was $2.29 to $8.54. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.